Analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to report ($0.76) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($0.80). Lexicon Pharmaceuticals posted earnings of ($0.16) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 375%. The company is scheduled to issue its next quarterly earnings results on Wednesday, March 11th.
On average, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of $0.83 per share for the current financial year, with EPS estimates ranging from $0.78 to $0.87. For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.40) to ($1.55). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The business had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The business’s revenue was up 4124.5% compared to the same quarter last year.
In other Lexicon Pharmaceuticals news, Director Christopher J. Sobecki purchased 25,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was bought at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the purchase, the director now owns 112,493 shares in the company, valued at approximately $286,857.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher J. Sobecki purchased 99,249 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was acquired at an average price of $2.41 per share, with a total value of $239,190.09. Following the completion of the purchase, the director now owns 13,645 shares of the company’s stock, valued at approximately $32,884.45. The disclosure for this purchase can be found here. Insiders have purchased a total of 178,749 shares of company stock valued at $474,560 over the last 90 days. 6.40% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in LXRX. Quantitative Systematic Strategies LLC raised its stake in Lexicon Pharmaceuticals by 67.2% in the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 8,302 shares during the last quarter. Wedbush Securities Inc. raised its stake in Lexicon Pharmaceuticals by 33.0% in the second quarter. Wedbush Securities Inc. now owns 194,339 shares of the biopharmaceutical company’s stock valued at $1,222,000 after buying an additional 48,182 shares during the last quarter. Swiss National Bank raised its stake in Lexicon Pharmaceuticals by 18.3% in the second quarter. Swiss National Bank now owns 88,614 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 13,700 shares during the last quarter. GSA Capital Partners LLP raised its stake in Lexicon Pharmaceuticals by 217.5% in the second quarter. GSA Capital Partners LLP now owns 87,132 shares of the biopharmaceutical company’s stock valued at $548,000 after buying an additional 59,685 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Lexicon Pharmaceuticals in the second quarter valued at about $92,000. Institutional investors own 96.27% of the company’s stock.
Shares of LXRX traded up $0.47 during midday trading on Wednesday, reaching $3.77. 1,995,599 shares of the stock were exchanged, compared to its average volume of 1,297,426. Lexicon Pharmaceuticals has a 52 week low of $1.13 and a 52 week high of $8.39. The company has a current ratio of 8.11, a quick ratio of 8.01 and a debt-to-equity ratio of 1.42. The company’s 50 day moving average is $3.63 and its two-hundred day moving average is $3.88. The company has a market capitalization of $400.65 million, a P/E ratio of -3.31 and a beta of 1.00.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
See Also: What is quantitative easing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.